๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer

โœ Scribed by Dennis L. Citrin; Tom F. Hogan


Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
503 KB
Volume
50
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Phase II evaluation of adriamycin in hum
โœ Robert M. O'Bryan; James K. Luce; Robert W. Talley; Jeffrey A. Gottlieb; Laurenc ๐Ÿ“‚ Article ๐Ÿ“… 1973 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 678 KB
The effects of gefitinib in tamoxifen-re
โœ Eleanor Gutteridge; Amit Agrawal; Robert Nicholson; Kwok Leung Cheung; John Robe ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 366 KB

## Abstract Estrogen receptor (ER)โ€positive acquired tamoxifenโ€resistant (TAMโ€R) MCFโ€7 breast cancer cell lines exhibit epidermal growth factor receptor (EGFR) expression/signaling and are growthโ€inhibited by gefitinib (IRESSA). We examined the effect of gefitinib on ERโ€positive TAMโ€R and ERโ€negati

Follow-up evaluation of a phase II prost
โœ Tjoa, B.A.; Simmons, S.J.; Elgamal, A.; Rogers, M.; Ragde, H.; Kenny, G.M.; Troy ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 150 KB ๐Ÿ‘ 1 views

## BACKGROUND. A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, including subjects with hormone-refract

Use of a hormone-sensitive (LNCaP) and a
โœ Pousette, ร…ke; Carlstrรถm, Kjell; Henriksson, Peter; Grande, Mirtha; Stege, Reinh ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 927 KB

## Background: In order to develop a hormone-resistant analog to the hormone sensitive cell-line lncap, different methods were tried. ## Methods: After almost one year of continuous culture in rpmi-1640, containing a low concentration of androgens, the hormone sensitive cell-line lncap became hor

A phase II study of recombinant human al
โœ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 306 KB ๐Ÿ‘ 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas